Ostriol 0.25 mcg (Capsule)
Medicine Details
| Category | Details |
|---|---|
| Generic | Calcitriol |
| Company | Nipro jmi pharma ltd |
Indications
- Post-menopausal osteoporosis
- Renal osteodystrophy
- Postsurgical hypoparathyroidism
- Idiopathic hypoparathyroidism
- Pseudohypoparathyroidism
- Secondary hyperparathyroidism in patients with moderate to severe chronic renal failure (pre-dialysis)
- Vitamin D dependent rickets
Pharmacology
Calcitriol is one of the most important active metabolites of vitamin D3. It promotes intestinal absorption of calcium, regulates bone mineralization, and stimulates osteoblastic activity in the skeleton.
Dosage & Administration
- Recommended dose of Calcitriol capsule for Post-menopausal Osteoporosis: 0.25 mcg twice daily
- Initial daily dose for Renal Osteodystrophy (dialysis patients): 0.25 mcg of Calcitriol capsule, with adjustments based on calcium levels
- Recommended initial dosage of Calcitriol capsule for Hypoparathyroidism and Rickets: 0.25 mcg/day, with possible dose adjustments at 2-4 weeks intervals
Interaction
Concomitant treatment with thiazide diuretics increases the risk of hypercalcemia. Careful dosage determination is needed for patients undergoing treatment with digitalis. Magnesium-containing drugs may cause hypermagnesemia.
Contraindications
Calcitriol is contraindicated in patients with known hypersensitivity to any of its ingredients and in all diseases associated with hypercalcemia.
Side Effects
- Early side effects of Ostriol injection: weakness, headache, nausea, dry mouth, muscle pain
- Late side effects: polyuria, anorexia, weight loss, conjunctivitis, hyperthermia, elevated BUN, hypertension, cardiac arrhythmias
Pregnancy & Lactation
Calcitriol may be used during pregnancy if the benefits outweigh the potential risk to the fetus. Mothers may breastfeed while taking Calcitriol, but monitoring of serum calcium levels of the mother and infant is recommended.
Precautions & Warnings
- Excessive dosage of Ostriol injection induces hypercalcemia and hypercalciuria
- Caution is advised for patients on digitalis, as hypercalcemia may precipitate cardiac arrhythmias
- Discontinuation of Ostriol injection therapy may result in rebound effect, appropriate titration downward is recommended
- Vitamin D and its derivatives should be withheld during treatment with Ostriol injection
- Non-aluminum phosphate-binding compound should be used to control serum phosphorus levels in patients undergoing dialysis
Use in Special Populations
- Recommended initial dosage of Ostriol for secondary hyperparathyroidism in adults and pediatric patients 3 years of age or older: 0.25 mcg/day, with possible increase to 0.5 mcg/day if necessary
- Recommended initial dosage of Ostriol for pediatric patients less than 3 years of age: 10 to 15 ng/kg/day
- No dosage adjustments are required for elderly patients
Overdose Effects
Administration of Ostriol injection in excess of requirements can cause hypercalcemia, hypercalciuria, and hyperphosphatemia. General treatment of hypercalcemia consists of immediate discontinuation of Ostriol injection therapy, low calcium diet, and withdrawal of calcium supplements.
Therapeutic Class
Vitamin in bone formation, Vitamin-D preparations
Storage Conditions
Keep in a dry place away from light and heat. Keep out of the reach of children.